Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ou

Rastogi, P.; O'Shaughnessy, J.; Martin, M.; Boyle, F.; Cortes, J.; Rugo, H.S.; Goetz, M.P.; Hamilton, E.P.; Huang, C.; Senkus, E.; Tryakin, A.; Cicin, I.; Testa, L.; Neven, P.; Huober, J.; Shao, Z.; Wei, R.; André, V.; Munoz, M.; San, A.B.; Shahir, A.; Harbeck, N.; Johnston, S.

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ouстатья

Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus

Авторы: Rastogi Priya, O'Shaughnessy Joyce, Martin Miguel, Boyle Frances, Cortes Javier, Rugo Hope S., Goetz Matthew P., Hamilton Erika P., Huang Chiun-Sheng, Senkus Elzbieta, Tryakin Alexey, Cicin Irfan, Testa Laura, Neven Patrick, Huober Jens, Shao Zhimin, Wei Ran, André Valérie, Munoz Maria, San Antonio Belen, Shahir Ashwin, Harbeck Nadia, Johnston Stephen
Журнал: Journal of Clinical Oncology
Год издания: 2024
Издательство: American Society of Clinical Oncology
Местоположение издательства: United States
DOI: 10.1200/jco.23.01994
Добавил в систему: Трякин Алексей Александрович

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ИНХС РАН

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Ouстатья